Resistant Hypertension With Comorbidities Therapeutics
1. Benicar patent expiration
Treatment: Use as an antihypertensive agent; Treatment of hypertension
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(9 years ago) | |
| US6878703 | COSETTE | Pharmaceutical composition |
Nov, 2021
(4 years ago) | |
|
US6878703 (Pediatric) | COSETTE | Pharmaceutical composition |
May, 2022
(3 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 04, 2013 |
| Pediatric Exclusivity(PED) | Aug 04, 2013 |
Drugs and Companies using OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 25 April, 2002
Dosage: TABLET
How can I launch a generic of BENICAR before it's drug patent expiration?
More Information on Dosage
BENICAR family patents
2. Edarbi patent expiration
Treatment: Treatment of hypertension
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5583141 | AZURITY | Heterocyclic compounds and their use as angiotensin antagonists |
Dec, 2013
(12 years ago) | |
| US5958961 | AZURITY | Pharmaceutical composition for angiotensin II-mediated diseases |
Jun, 2014
(11 years ago) | |
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(1 year, 1 day ago) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 25 February, 2011
Dosage: TABLET
How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage
EDARBI family patents
3. Inspra patent
expiration
Treatment: Treatment of conditions for which an aldosterone receptor blocker is indicated, such as hypertension, heart failure, and post-myocardial infarction; Use of eplerenone in combination with an angiotensi...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6863902 | UPJOHN | Immediate release eplerenone compositions |
Apr, 2020
(5 years ago) | |
|
US6558707 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6747020 (Pediatric) | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
May, 2020
(5 years ago) | |
|
US7157101 (Pediatric) | UPJOHN | Micronized eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6495165 (Pediatric) | UPJOHN | Eplerenone compositions having improved bioavailability |
Jun, 2020
(5 years ago) | |
|
US6410524 (Pediatric) | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
May, 2020
(5 years ago) | |
|
US6410054 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6534093 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Jun, 2020
(5 years ago) | |
|
US6863902 (Pediatric) | UPJOHN | Immediate release eplerenone compositions |
Oct, 2020
(5 years ago) | |
| US6410524 | UPJOHN | Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease |
Nov, 2019
(6 years ago) | |
| US6410054 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US6747020 | UPJOHN | Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
Nov, 2019
(6 years ago) | |
| US6534093 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US7157101 | UPJOHN | Micronized eplerenone compositions |
Dec, 2019
(6 years ago) | |
| US6495165 | UPJOHN | Eplerenone compositions having improved bioavailability |
Dec, 2019
(6 years ago) | |
| US6558707 | UPJOHN | Immediate release eplerenone compositions |
Dec, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jul 31, 2011 |
Drugs and Companies using EPLERENONE ingredient
Market Authorisation Date: 27 September, 2002
Dosage: TABLET
How can I launch a generic of INSPRA before it's drug patent expiration?
More Information on Dosage
INSPRA family patents
4. Tryvio patent expiration
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin converting enzyme inhibitor, to lower blood pressure in adult patients who are not adequately contr...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324232 | IDORSIA | 4-pyrimidinesulfamide derivative |
Sep, 2029
(3 years from now) | |
| US10919881 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11787782 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Mar, 2038
(12 years from now) | |
| US11680058 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Jul, 2038
(12 years from now) | |
| US11174247 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Nov, 2037
(11 years from now) | |
| US12297189 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Dosage: TABLET
More Information on Dosage
TRYVIO family patents